lapatinib ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 1548 231277-92-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lapatinib tosilate hydrate
  • lapatinib tosilate
  • lapatinib
  • GW 572016X
  • tyverb
  • lapatinib ditosylate
  • GW572016F
  • lapatinib ditosilate
  • lapatinib ditosilate hydrate
  • lapatinib ditosylate hydrate
A quinazoline derivative that inhibits EPIDERMAL GROWTH FACTOR RECEPTOR and HER2 (RECEPTOR, ERBB-2) tyrosine kinases. It is used for the treatment of advanced or metastatic breast cancer, where tumors overexpress HER2.
  • Molecular weight: 581.06
  • Formula: C29H26ClFN4O4S
  • CLOGP: 5.82
  • LIPINSKI: 2
  • HAC: 8
  • HDO: 2
  • TPSA: 106.35
  • ALOGS: -4.42
  • ROTB: 11

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.25 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 30.73 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
June 10, 2008 EMA
March 13, 2007 FDA NOVARTIS PHARMS CORP

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome 1854.14 20.69 574 23090 22441 63442917
Diarrhoea 1520.82 20.69 1572 22092 713794 62751564
Disease progression 856.30 20.69 545 23119 122213 63343145
Metastases to central nervous system 646.51 20.69 226 23438 12879 63452479
Malignant neoplasm progression 394.13 20.69 290 23374 81831 63383527
Neutropenia 320.31 20.69 359 23305 174646 63290712
Paronychia 309.36 20.69 105 23559 5460 63459898
Metastases to liver 273.12 20.69 146 23518 23493 63441865
Metastases to lung 266.05 20.69 118 23546 12632 63452726
Dehydration 254.75 20.69 318 23346 173036 63292322
Metastases to bone 199.33 20.69 114 23550 20905 63444453
Ejection fraction decreased 190.29 20.69 113 23551 22219 63443139
Skin toxicity 186.12 20.69 69 23595 4645 63460713
Vomiting 181.71 20.69 537 23127 559080 62906278
Breast cancer metastatic 181.66 20.69 89 23575 11929 63453429
Blood bilirubin increased 166.38 20.69 126 23538 37014 63428344
Death 163.30 20.69 401 23263 373980 63091378
Metastases to lymph nodes 155.83 20.69 71 23593 8087 63457271
Mucosal inflammation 138.56 20.69 125 23539 46803 63418555
Skin fissures 136.18 20.69 72 23592 11316 63454042
Jaundice 132.69 20.69 100 23564 29151 63436207
Metastases to skin 123.18 20.69 39 23625 1624 63463734
Hypokalaemia 113.34 20.69 165 23499 103639 63361719
Gastrointestinal toxicity 110.07 20.69 55 23609 7686 63457672
Hepatic function abnormal 107.79 20.69 98 23566 37044 63428314
Dry skin 104.24 20.69 117 23547 56770 63408588
Hyperbilirubinaemia 100.95 20.69 59 23605 11255 63454103
Stomatitis 97.84 20.69 181 23483 138544 63326814
Rash 96.89 20.69 439 23225 560432 62904926
Nausea 96.36 20.69 594 23070 853877 62611481
Hepatotoxicity 92.65 20.69 90 23574 36951 63428407
Febrile neutropenia 87.88 20.69 158 23506 118291 63347067
Cardiotoxicity 86.01 20.69 48 23616 8390 63456968
Lymphangiosis carcinomatosa 83.18 20.69 28 23636 1417 63463941
Pyrexia 80.18 20.69 367 23297 470111 62995247
Alanine aminotransferase increased 78.99 20.69 140 23524 103630 63361728
Haematotoxicity 76.09 20.69 46 23618 9330 63456028
Decreased appetite 75.40 20.69 235 23429 250817 63214541
Condition aggravated 73.59 20.69 29 23635 402188 63063170
Drug hypersensitivity 72.44 20.69 14 23650 310673 63154685
Weight increased 66.95 20.69 9 23655 260783 63204575
Joint swelling 64.38 20.69 21 23643 327645 63137713
Drug ineffective 62.48 20.69 192 23472 1044573 62420785
Pleural effusion 59.95 20.69 117 23547 93093 63372265
Arthralgia 59.69 20.69 75 23589 569635 62895723
Therapeutic product effect decreased 59.57 20.69 3 23661 193184 63272174
Maternal exposure during pregnancy 55.52 20.69 8 23656 220054 63245304
Off label use 55.18 20.69 105 23559 674357 62791001
Dermatitis acneiform 52.50 20.69 29 23635 4967 63460391
Asthenia 51.56 20.69 280 23384 383324 63082034
Neoplasm progression 48.86 20.69 64 23600 36364 63428994
Glossodynia 48.80 20.69 5 23659 178871 63286487
Fall 48.42 20.69 45 23619 392289 63073069
Breast cancer 47.17 20.69 73 23591 48310 63417048
Aspartate aminotransferase increased 44.87 20.69 102 23562 90175 63375183
Skin exfoliation 44.80 20.69 67 23597 43035 63422323
Sinusitis 43.66 20.69 15 23649 226638 63238720
Metastasis 43.47 20.69 26 23638 5171 63460187
Completed suicide 42.66 20.69 3 23661 145670 63319688
Cellulitis 42.29 20.69 94 23570 81864 63383494
Superior vena cava syndrome 42.04 20.69 14 23650 685 63464673
Neurotoxicity 41.94 20.69 41 23623 16949 63448409
Biliary dilatation 40.98 20.69 19 23645 2250 63463108
Thrombocytopenia 40.32 20.69 136 23528 151021 63314337
Leukopenia 40.28 20.69 89 23575 77201 63388157
Pain 40.04 20.69 142 23522 740486 62724872
Musculoskeletal stiffness 39.60 20.69 10 23654 184608 63280750
Product dose omission issue 39.45 20.69 19 23645 234294 63231064
Neuropathy peripheral 39.35 20.69 112 23552 113555 63351803
Ascites 39.07 20.69 61 23603 40667 63424691
Neoplasm 37.55 20.69 27 23637 7318 63458040
Onychalgia 37.54 20.69 14 23650 957 63464401
Hypertension 36.89 20.69 30 23634 279273 63186085
Infusion related reaction 36.85 20.69 23 23641 245498 63219860
Wound 36.68 20.69 8 23656 163255 63302103
Discomfort 36.02 20.69 9 23655 167365 63297993
Transaminases 35.65 20.69 8 23656 84 63465274
Second primary malignancy 35.63 20.69 27 23637 7926 63457432
Therapeutic product effect incomplete 35.42 20.69 3 23661 125053 63340305
Metastatic neoplasm 34.66 20.69 21 23643 4274 63461084
Limbal stem cell deficiency 34.46 20.69 6 23658 13 63465345
Swelling 32.30 20.69 33 23631 275345 63190013
Radiation necrosis 32.11 20.69 10 23654 394 63464964
Erythema 31.95 20.69 140 23524 175611 63289747
Breast cancer recurrent 31.92 20.69 20 23644 4321 63461037
Feeling abnormal 31.89 20.69 8 23656 148384 63316974
Metastases to spine 31.80 20.69 18 23646 3231 63462127
Nail disorder 31.36 20.69 31 23633 12984 63452374
Recurrent cancer 30.87 20.69 15 23649 1972 63463386
Alopecia 30.73 20.69 49 23615 337487 63127871
Onycholysis 30.49 20.69 14 23650 1622 63463736
Left ventricular dysfunction 29.72 20.69 29 23635 11959 63453399
Asthma 29.16 20.69 6 23658 127555 63337803
Brain oedema 29.11 20.69 31 23633 14164 63451194
Breast neoplasm 29.04 20.69 13 23651 1419 63463939
Pericardial effusion 28.80 20.69 45 23619 30013 63435345
Exposure during pregnancy 28.74 20.69 11 23653 155536 63309822
Plantar erythema 28.51 20.69 8 23656 218 63465140
Treatment failure 28.03 20.69 20 23644 199023 63266335
Abdominal discomfort 27.89 20.69 48 23616 320837 63144521
Radiation pneumonitis 27.80 20.69 13 23651 1570 63463788
Nail infection 27.49 20.69 15 23649 2508 63462850
Drug interaction 27.38 20.69 27 23637 229104 63236254
Tumour marker increased 27.28 20.69 19 23645 4896 63460462
Performance status decreased 27.18 20.69 17 23647 3661 63461697
Mobility decreased 27.08 20.69 6 23658 121153 63344205
Neoplasm recurrence 26.86 20.69 15 23649 2623 63462735
Neoplasm malignant 26.27 20.69 43 23621 29818 63435540
Injection site pain 26.02 20.69 8 23656 129792 63335566
Gamma-glutamyltransferase increased 25.97 20.69 46 23618 33985 63431373
Contusion 25.50 20.69 12 23652 150032 63315326
Arthritis 25.39 20.69 6 23658 115915 63349443
Botryomycosis 25.36 20.69 5 23659 26 63465332
Lower respiratory tract infection 25.04 20.69 9 23655 132298 63333060
Central nervous system lesion 25.01 20.69 25 23639 10610 63454748
Vascular device infection 24.61 20.69 21 23643 7291 63458067
Brain neoplasm 24.52 20.69 17 23647 4349 63461009
Anal erythema 24.47 20.69 7 23657 205 63465153
Drug intolerance 24.32 20.69 49 23615 308612 63156746
Skin mass 24.02 20.69 19 23645 5936 63459422
Abdominal pain 23.88 20.69 189 23475 293267 63172091
Dyschezia 23.24 20.69 13 23651 2281 63463077
Product use issue 23.04 20.69 29 23635 220491 63244867
Ingrowing nail 22.45 20.69 13 23651 2436 63462922
Psoriasis 22.29 20.69 3 23661 86954 63378404
Lung infiltration 21.90 20.69 27 23637 14436 63450922
Metastases to meninges 21.72 20.69 13 23651 2589 63462769
Malignant pleural effusion 21.70 20.69 13 23651 2593 63462765
Hormone receptor positive breast cancer 21.61 20.69 8 23656 536 63464822
Bone cancer metastatic 21.40 20.69 6 23658 163 63465195
Osteonecrosis of jaw 21.25 20.69 43 23621 35080 63430278
Pneumonitis 21.16 20.69 43 23621 35179 63430179
Hyperhidrosis 20.98 20.69 7 23657 107829 63357529
Epistaxis 20.77 20.69 67 23597 72658 63392700

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Duodenal ulcer perforation 53.49 36.55 12 1095 1620 34954204
Diarrhoea 43.46 36.55 57 1050 389855 34565969
Metastases to lung 36.58 36.55 13 1094 9307 34946517

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome 1166.08 20.25 381 15894 32753 79695360
Diarrhoea 1036.46 20.25 1066 15209 879423 78848690
Disease progression 549.36 20.25 384 15891 183978 79544135
Metastases to central nervous system 405.64 20.25 145 16130 16230 79711883
Malignant neoplasm progression 298.24 20.25 236 16039 135754 79592359
Metastases to lung 240.11 20.25 102 16173 18061 79710052
Metastases to liver 208.47 20.25 106 16169 28208 79699905
Dehydration 175.79 20.25 234 16041 247953 79480160
Paronychia 174.06 20.25 64 16211 7744 79720369
Breast cancer metastatic 164.43 20.25 63 16212 8539 79719574
Metastases to bone 155.60 20.25 83 16192 24344 79703769
Vomiting 142.30 20.25 374 15901 665454 79062659
Ejection fraction decreased 136.28 20.25 86 16189 34491 79693622
Metastases to skin 135.33 20.25 37 16238 1702 79726411
Metastases to lymph nodes 132.79 20.25 57 16218 10340 79717773
Gastrointestinal toxicity 122.14 20.25 50 16225 8059 79720054
Neutropenia 113.21 20.25 207 16068 287503 79440610
Skin toxicity 97.75 20.25 43 16232 8271 79719842
Skin fissures 93.44 20.25 48 16227 13025 79715088
Mucosal inflammation 91.50 20.25 94 16181 75486 79652627
Death 91.39 20.25 288 15987 566226 79161887
Hepatotoxicity 87.18 20.25 77 16198 51275 79676838
Hyperbilirubinaemia 81.92 20.25 55 16220 24463 79703650
Nausea 81.15 20.25 397 15878 956799 78771314
Hypokalaemia 78.44 20.25 120 16155 143920 79584193
Blood bilirubin increased 75.90 20.25 80 16195 66152 79661961
Jaundice 75.01 20.25 72 16203 53277 79674836
Lymphangiosis carcinomatosa 68.48 20.25 23 16252 2131 79725982
Rash 66.39 20.25 263 16012 578095 79150018
Cardiotoxicity 62.58 20.25 36 16239 12203 79715910
Haematotoxicity 62.12 20.25 39 16236 15480 79712633
Dry skin 58.88 20.25 71 16204 67924 79660189
Stomatitis 56.84 20.25 105 16170 146652 79581461
Condition aggravated 51.51 20.25 19 16256 501105 79227008
Asthenia 51.05 20.25 223 16052 511466 79216647
Dermatitis acneiform 39.71 20.25 25 16250 9968 79718145
Decreased appetite 39.38 20.25 156 16119 342262 79385851
Metastases to spine 37.17 20.25 18 16257 4306 79723807
Drug hypersensitivity 36.84 20.25 8 16267 298908 79429205
Onycholysis 35.35 20.25 14 16261 2069 79726044
Transaminases 35.19 20.25 7 16268 76 79728037
Weight increased 35.06 20.25 7 16268 277379 79450734
Biliary dilatation 34.67 20.25 15 16260 2771 79725342
Tumour marker increased 34.38 20.25 17 16258 4255 79723858
Onychalgia 33.60 20.25 11 16264 941 79727172
Limbal stem cell deficiency 33.32 20.25 6 16269 36 79728077
Drug interaction 33.19 20.25 22 16253 415161 79312952
Hepatic function abnormal 33.04 20.25 56 16219 73051 79655062
Abdominal pain 33.02 20.25 162 16113 389407 79338706
Metastasis 31.91 20.25 19 16256 6861 79721252
Fall 31.35 20.25 32 16243 487597 79240516
Breast cancer recurrent 30.54 20.25 14 16261 2963 79725150
Hormone receptor positive breast cancer 29.45 20.25 8 16267 359 79727754
Neoplasm progression 29.43 20.25 44 16231 51638 79676475
Second primary malignancy 29.43 20.25 24 16251 14326 79713787
Pyrexia 28.03 20.25 235 16040 678474 79049639
Osteonecrosis of jaw 27.82 20.25 39 16236 43187 79684926
Pleural effusion 27.17 20.25 78 16197 145184 79582929
Breast cancer 27.17 20.25 34 16241 33747 79694366
Neurotoxicity 26.59 20.25 33 16242 32485 79695628
Recurrent cancer 25.56 20.25 12 16263 2681 79725432
Metastases to the mediastinum 25.43 20.25 8 16267 602 79727511
Joint swelling 24.86 20.25 14 16261 288632 79439481
Botryomycosis 24.75 20.25 5 16270 59 79728054
Arthralgia 23.62 20.25 51 16224 571752 79156361
Metastatic neoplasm 23.58 20.25 14 16261 5028 79723085
Cholangitis 23.36 20.25 20 16255 12756 79715357
Hypertension 23.28 20.25 20 16255 330972 79397141
Left ventricular dysfunction 23.26 20.25 24 16251 19337 79708776
Neoplasm recurrence 23.17 20.25 13 16262 4201 79723912
Pericardial effusion 23.01 20.25 37 16238 46200 79681913
Central nervous system lesion 22.58 20.25 20 16255 13348 79714765
Skin mass 22.04 20.25 16 16259 8047 79720066
Alanine aminotransferase increased 21.92 20.25 78 16197 162492 79565621
Neuropathy peripheral 21.86 20.25 71 16204 141234 79586879
Cellulitis 21.80 20.25 60 16215 109000 79619113
Drug ineffective 21.58 20.25 131 16144 1080782 78647331
Infusion related reaction 21.56 20.25 10 16265 230227 79497886
Disease recurrence 21.55 20.25 35 16240 44074 79684039
Product dose omission issue 21.32 20.25 12 16263 247525 79480588
Radiation pneumonitis 21.26 20.25 12 16263 3921 79724192
Plantar erythema 21.19 20.25 6 16269 314 79727799
Performance status decreased 21.10 20.25 14 16261 6099 79722014
Gastric neoplasm 20.47 20.25 6 16269 355 79727758
Neoplasm 20.30 20.25 16 16259 9100 79719013

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EH01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
FDA MoA N0000175076 Protein Kinase Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
HER2-positive carcinoma of breast indication 427685000
Torsades de pointes contraindication 31722008
Hypokalemia contraindication 43339004
Hepatic failure contraindication 59927004
Interstitial pneumonia contraindication 64667001
Left heart failure contraindication 85232009
Prolonged QT interval contraindication 111975006
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Drug-induced hepatitis contraindication 235876009
Pregnancy, function contraindication 289908002
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Congenital long QT syndrome contraindication 442917000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.62 Basic
pKa2 4.99 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Epidermal growth factor receptor Kinase INHIBITOR Kd 9.04 CHEMBL CHEMBL
Receptor tyrosine-protein kinase erbB-2 Kinase INHIBITOR Kd 8.15 CHEMBL CHEMBL
Platelet-derived growth factor receptor beta Kinase IC50 5.07 CHEMBL
Tyrosine-protein kinase ABL1 Kinase IC50 4.64 CHEMBL
Solute carrier organic anion transporter family member 1B1 Transporter WOMBAT-PK
Cyclin-dependent kinase 2 Kinase IC50 4.96 CHEMBL
Insulin receptor Kinase AGONIST IC50 4.77 CHEMBL
Receptor tyrosine-protein kinase erbB-4 Kinase Kd 7.27 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 5.59 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 5.44 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 5.48 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 7 Kinase Kd 5.36 CHEMBL
Receptor tyrosine-protein kinase erbB-3 Kinase Kd 5.26 CHEMBL
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta Kinase Kd 6.17 CHEMBL
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma Kinase Kd 5.12 CHEMBL
Phosphatidylinositol 4-kinase beta Kinase Kd 6.03 CHEMBL
Multidrug resistance protein 1 Transporter WOMBAT-PK
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 5.96 CHEMBL
ATP-binding cassette sub-family G member 2 Transporter WOMBAT-PK
Tubulin alpha-1A chain Structural Kd 7.27 CHEMBL

External reference:

IDSource
4026029 VUID
N0000179782 NUI
D04024 KEGG_DRUG
388082-78-8 SECONDARY_CAS_RN
4026029 VANDF
C1506770 UMLSCUI
FMM PDB_CHEM_ID
CHEMBL554 ChEMBL_ID
CHEMBL1201179 ChEMBL_ID
D000077341 MESH_DESCRIPTOR_UI
DB01259 DRUGBANK_ID
5692 IUPHAR_LIGAND_ID
8378 INN_ID
0VUA21238F UNII
208908 PUBCHEM_CID
480167 RXNORM
339254 MMSL
d06672 MMSL
012020 NDDF
012022 NDDF
425466009 SNOMEDCT_US
425820005 SNOMEDCT_US
426238006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TYKERB HUMAN PRESCRIPTION DRUG LABEL 1 0078-0671 TABLET 250 mg ORAL NDA 34 sections
TYKERB HUMAN PRESCRIPTION DRUG LABEL 1 0078-0671 TABLET 250 mg ORAL NDA 34 sections
TYKERB HUMAN PRESCRIPTION DRUG LABEL 1 0078-0671 TABLET 250 mg ORAL NDA 34 sections
Lapatinib Human Prescription Drug Label 1 68180-801 TABLET 250 mg ORAL ANDA 28 sections
Lapatinib Human Prescription Drug Label 1 68180-801 TABLET 250 mg ORAL ANDA 28 sections